Related Experiment Video
Updated: Jul 30, 2025
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
5.9K
Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential
Leiling Liu1, Jiahui Hu1, Hao Lei1
1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Cardiovascular Drugs and Therapy
|May 15, 2023
Summary
Regulatory T cells (Tregs) show a protective role in pathological cardiac hypertrophy. Treg-based therapies offer a promising new approach for treating this condition by targeting immune-inflammatory responses.
Area of Science:
- Immunology
- Cardiology
- Cell Biology
Background:
- Pathological cardiac hypertrophy is associated with immune-inflammatory injury.
- Regulatory T cells (Tregs) are key in suppressing immune responses.
- The specific function of Tregs in cardiac hypertrophy is not fully understood.
Purpose of the Study:
- To review the role and mechanisms of Tregs in pathological cardiac hypertrophy.
- To explore Treg-based therapies for cardiac hypertrophy.
- To identify challenges and future directions for Treg therapies.
Main Methods:
- Literature review of studies on Tregs and cardiac hypertrophy.
- Analysis of Treg function in various cardiac hypertrophy models.
- Evaluation of current and potential Treg-based therapeutic strategies.
Main Results:
- Tregs appear protective in various forms of cardiac hypertrophy, including pressure overload, myocardial infarction, and metabolic disorders.
- Clinical trials indicate the safety and efficacy of Treg-based therapies.
- Engineered antigen-specific Tregs show potential for enhanced clinical application.
Conclusions:
- Modulating immune-inflammatory responses through Treg-based therapies is a promising strategy for preventing and treating pathological cardiac hypertrophy.
- Further research and clinical development are needed to optimize Treg therapies.
- Treg-based approaches represent a novel therapeutic avenue in cardiovascular medicine.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
7.3K
11:51Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
10.4K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
18
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
18
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
17
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
473
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
473
01:29Cardiomyopathy V: Interprofessional Care
19
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
19
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K